相关实验视频

Updated: Jun 22, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

对非小细胞肺癌检查点抑制剂的风险和安全概况:系统性审查

Sara Maria Majernikova^1,2

¹Department for Continuing Education, The University of Oxford, Oxford, UK.

Human vaccines & immunotherapeutics

|June 27, 2024

概括

免疫检查点抑制剂 (ICI) 对治疗非小细胞肺癌 (NSCLC) 有望,与传统疗法相比,提高生存率和降低死亡率. 基于纳米粒子的ICI提供了先进的治疗选择,尽管潜在的副作用需要仔细管理.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
纳米技术纳米技术

背景情况:

非小细胞肺癌 (NSCLC) 是一个重大的全球卫生挑战,死亡率高,生存率低.
免疫检查点抑制剂 (ICI) 已成为NSCLC的有希望的治疗策略,因为它们能够利用免疫系统对抗癌细胞.
通过ICI过度刺激免疫系统可能导致不良影响,需要研究更安全,更有效的输送方法.

研究的目的:

审查基于纳米粒子的免疫检查点抑制剂 (ICI) 对非小细胞肺癌 (NSCLC) 治疗的最新进展.
与传统疗法相比,评估纳米粒子输送ICI的疗效和安全性.
为了确定目前的局限性和未来的方向,纳米粒子为NSCLC的免疫疗法.

主要方法:

在PubMed,Scopus和Web of Science数据库中进行了系统的文献搜索.
包括的出版物包括38项试验,涉及16,781名参与者.
混合效应模型被用于分析治疗效应和子组差异.

主要成果:

免疫检查点抑制剂 (ICI) 对NSCLC的治疗有效性产生了显著的积极影响.
与传统治疗方案相比,ICI与患者死亡率的降低有关.
基于纳米粒子的输送系统正在成为优化ICI治疗的关键研究领域.

结论:

基于纳米粒子的免疫检查点抑制剂在非小细胞肺癌治疗中提供了一个有前途的前沿,有可能改善患者的治疗结果.
与传统治疗相比,ICI显示出更高的疗效和降低的死亡率,支持其扩大临床使用.
对纳米粒子配方的进一步研究可能会减轻与免疫相关的不良事件,并优化NSCLC治疗策略.

关键词:

不良事件是不良事件.抗瘤免疫力免疫力检查点抑制剂检查点抑制剂其他非小细胞肺癌.审查审查审查审查审查审查

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...